Human Papillomavirus in Menstrual Blood

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Kidong Kim, Seoul National University Bundang Hospital
ClinicalTrials.gov Identifier:
NCT01506128
First received: January 3, 2012
Last updated: March 4, 2013
Last verified: March 2013

January 3, 2012
March 4, 2013
January 2012
January 2013   (final data collection date for primary outcome measure)
HPV detection rate in menstrual blood [ Time Frame: First period after enrollment usually within 2 months after enrollment ] [ Designated as safety issue: No ]
The first menstrual period after enrollment is assumed to occur within 2 months. At that time, the participant used pads and send the used pads to investigators. The investigator do procedures to detect HPV in pads.
Same as current
Complete list of historical versions of study NCT01506128 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Human Papillomavirus in Menstrual Blood
Exploration of Optimal Experimental Settings to Detect Human Papillomavirus From Menstrual Blood in Women With High-grade Squamous Intraepithelial Lesion or High-risk Human Papillomavirus Infection

The investigators tried to know whether a virus causing cervical cancer could be detected in menstrual blood and to set up a experimental setting to detect the virus.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Menstrual blood in pad

Non-Probability Sample

Premenopausal women with HSIL at Pap test or high-risk HPV

Human Papillomavirus
Other: Collecting a Pad used at the first menstrual period after enrollment
Collecting a Pad used at the first menstrual period after enrollment
HPV
Premenopausal women with HSIL in Pap test or high-risk HPV
Intervention: Other: Collecting a Pad used at the first menstrual period after enrollment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
19
January 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Premenopausal women with HSIL at Pap test or high-risk HPV

Exclusion Criteria:

  • Suspicious cancer
Female
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT01506128
SNUBH_GO_001
No
Kidong Kim, Seoul National University Bundang Hospital
Seoul National University Hospital
Not Provided
Not Provided
Seoul National University Hospital
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP